Cargando…
Efficacy and Safety of Canagliflozin 300 mg in Overweight and Obese Type 2 Diabetes Mellitus Patients in a Real-world Setting: COLOR Study
BACKGROUND AND AIMS: To assess the efficacy and safety of canagliflozin (CANA, 300 mg/d) in overweight and obese patients with type 2 diabetes mellitus (T2DM). METHODS: In a single centre, retrospective, observational study, we included overweight or obese patients with T2DM who had HbA1c >7% and...
Autores principales: | Aneja, Pankaj, Bhalla, Gaurav, Parvesh, Neeti, Aneja, Kunal, Aneja, Kashish |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683679/ https://www.ncbi.nlm.nih.gov/pubmed/31641632 http://dx.doi.org/10.4103/ijem.IJEM_55_19 |
Ejemplares similares
-
A rare case of OEIS complex – newer approach to diagnosis of exstrophy bladder by color doppler and its differentiation from simple omphalocele
por: Aneja, Kavita
Publicado: (2017) -
Case Reports: The Art of Writing, the Importance of Publishing it and Avoiding Facing Rejection
por: Aneja, Kunal, et al.
Publicado: (2022) -
Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
por: Stafford, Sara, et al.
Publicado: (2022) -
A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus
por: Prasanna Kumar, K. M., et al.
Publicado: (2017) -
COVID-19 in the Americas: the role of collaborating centers in understanding lessons and best practices in pandemic preparedness and response
por: Nardi, Francesca, et al.
Publicado: (2023)